Terms: = Breast cancer AND HER1, YOR227W
306 results:
1. Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
[TBL] [Abstract] [Full Text] [Related]
2. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy.
Chaudhary LN; Jorns JM; Sun Y; Cheng YC; Kamaraju S; Burfeind J; Gonyo MB; Kong AL; Patten C; Yen T; Cortina CS; Carson E; Johnson N; Bergom C; Tsaih SW; Banerjee A; Wang Y; Chervoneva I; Weil E; Chitambar CR; Rui H
Breast Cancer Res Treat; 2023 Oct; 201(3):387-396. PubMed ID: 37460683
[TBL] [Abstract] [Full Text] [Related]
3. Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for breast cancer Patients.
Wignarajah S; Chianella I; Tothill IE
Biosensors (Basel); 2023 Mar; 13(3):. PubMed ID: 36979567
[TBL] [Abstract] [Full Text] [Related]
4. The Effect of Aflatoxin B1 on Tumor-Related Genes and Phenotypic Characters of MCF7 and MCF10A Cells.
Adam MAA; Kamal LZM; Kanakal M; Babu D; Dahham SS; Tabana Y; Lok B; Bermoy BM; Yunus MA; Than LTL; Barakat K; Sandai D
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233156
[TBL] [Abstract] [Full Text] [Related]
5. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Drago JZ; Ferraro E; Abuhadra N; Modi S
Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
[TBL] [Abstract] [Full Text] [Related]
6. Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients.
Ramić S; Paić F; Smajlbegović V; Perić Balja M; Hiršl L; Marton I; Knežević F
Croat Med J; 2022 Apr; 63(2):126-140. PubMed ID: 35505646
[TBL] [Abstract] [Full Text] [Related]
7. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX; Wong ALA; Ow S; Sundar R; Tan DSP; Soo RA; Chee CE; Lim JSJ; Yong WP; Lim SE; Goh BC; Wang L; Lee SC
Target Oncol; 2022 Mar; 17(2):141-151. PubMed ID: 35195837
[TBL] [Abstract] [Full Text] [Related]
8. Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.
MacNeil IA; Khan SA; Sen A; Soltani SM; Burns DJ; Sullivan BF; Laing LG
Cell Commun Signal; 2022 Jan; 20(1):4. PubMed ID: 34998412
[TBL] [Abstract] [Full Text] [Related]
9. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
10. Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress.
Sharma B; Singh VJ; Chawla PA
Bioorg Chem; 2021 Nov; 116():105393. PubMed ID: 34628226
[TBL] [Abstract] [Full Text] [Related]
11. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of her1-or HER2-targeted drugs.
Okita K; Imai K; Kato K; Sugiura R; Endo Y; Masuko K; Tomioka Y; Masuko T
Biochem Biophys Res Commun; 2021 Oct; 576():59-65. PubMed ID: 34482024
[TBL] [Abstract] [Full Text] [Related]
12. [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer].
Wang X; Yuan P
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):511-515. PubMed ID: 34034468
[TBL] [Abstract] [Full Text] [Related]
13. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract] [Full Text] [Related]
14. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.
Yuan Y; Lee JS; Yost SE; Stiller T; Blanchard MS; Padam S; Katheria V; Kim H; Sun C; Tang A; Martinez N; Patel ND; Sedrak MS; Waisman J; Li D; Sanani S; Presant CA; Mortimer J
J Geriatr Oncol; 2021 Jun; 12(5):752-758. PubMed ID: 33663941
[TBL] [Abstract] [Full Text] [Related]
15. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs.
Sharko AC; Lim CU; McDermott MSJ; Hennes C; Philavong KP; Aiken T; Tatarskiy VV; Roninson IB; Broude EV
Cells; 2021 Jan; 10(1):. PubMed ID: 33445730
[TBL] [Abstract] [Full Text] [Related]
16. PI3K/AKT/mTOR Signaling Pathway in breast cancer: From Molecular Landscape to Clinical Aspects.
Miricescu D; Totan A; Stanescu-Spinu II; Badoiu SC; Stefani C; Greabu M
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375317
[TBL] [Abstract] [Full Text] [Related]
17. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
18. Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway.
Zhang L; Liu Q; Huang L; Yang F; Liu A; Zhang J
Biochem Biophys Res Commun; 2020 Oct; 531(3):364-371. PubMed ID: 32800546
[TBL] [Abstract] [Full Text] [Related]
19. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.
Kaumaya PT
Future Oncol; 2020 Aug; 16(23):1767-1791. PubMed ID: 32564612
[TBL] [Abstract] [Full Text] [Related]
20. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract] [Full Text] [Related]
[Next]
